Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib Plus Camrelizumab in Advanced Solid Tumors
NCT03827837Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib and camrelizumab in renal cell carcinoma (RCC), urothelial carcinoma (UC), ovarian cancer and 2 more, sponsored by Hengrui. Primary endpoint: Overall Response Rate up to 2 years. Status: unknown.
02
Drugs
famitinibcamrelizumab
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03827837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827837.